Modality
Vaccine
MOA
PARPi
Target
KIF18A
Pathway
PD-1/PD-L1
CTCLRAGIST
Development Pipeline
Preclinical
~Jun 2021
→ ~Sep 2022
Phase 1
Dec 2022
→ Jan 2030
Phase 1Current
NCT08446157
2,220 pts·RA
2023-08→2025-05·Recruiting
NCT08498651
2,633 pts·RA
2022-12→2030-01·Terminated
4,853 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-05-0211mo agoInterim· RA
2030-01-083.8y awayInterim· RA
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030
P1
Termina…
P1
Recruit…
Catalysts
Interim
2025-05-02 · 11mo ago
RA
Interim
2030-01-08 · 3.8y away
RA
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08446157 | Phase 1 | RA | Recruiting | 2220 | VA |
| NCT08498651 | Phase 1 | RA | Terminated | 2633 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Niranesiran | Johnson & Johnson | Phase 2 | KIF18A | |
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| Riluinavolisib | Moderna | NDA/BLA | KIF18A | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| ALN-3958 | Alnylam | Phase 2 | MALT1 | |
| Cevifotisoran | Neurocrine | Approved | CD47 | |
| LEG-6533 | Legend Biotech | NDA/BLA | VEGF | |
| LEG-9870 | Legend Biotech | Phase 1 | CGRP |